Codexis - expects Q2 2026 revenue of at least $14.80 mln - SEC filing

Codexis, Inc. (NASDAQ: CDXS) has indicated in a recent SEC filing that it expects to report revenue of at least $14.80 million for the second quarter of 2026. This projection aligns with the company’s ongoing efforts to scale its biocatalysis-based manufacturing capabilities and expand its commercial partnerships in the pharmaceutical sector.

The company previously reported revenue of $15.2 million for the first quarter of 2026, maintaining its full-year financial guidance. Codexis continues to advance its ECO Synthesis® Manufacturing Platform, which is designed to improve the quality and scalability of complex therapeutics such as siRNA. Recent milestones include successful development of platform capabilities, receipt of ISO 9001 certification, and biocatalysis-enabled pharmaceutical product that received FDA approval.

Looking ahead, Codexis plans to apply for a building permit for its ECO GMP Manufacturing Center in Q2 2026 and initiate retrofit construction in the second half of the year. The company also remains focused on expanding strategic partnerships and advancing clinical-stage manufacturing agreements.